nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—POR—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0597	0.233	CbGpPWpGaD
Nilutamide—Nocturia—Varenicline—nicotine dependence	0.0336	0.0452	CcSEcCtD
Nilutamide—Photophobia—Varenicline—nicotine dependence	0.0293	0.0394	CcSEcCtD
Nilutamide—CYP2C8—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0247	0.0966	CbGpPWpGaD
Nilutamide—Libido decreased—Varenicline—nicotine dependence	0.0244	0.0328	CcSEcCtD
Nilutamide—Hot flush—Varenicline—nicotine dependence	0.0242	0.0325	CcSEcCtD
Nilutamide—Menopausal symptoms—Varenicline—nicotine dependence	0.024	0.0323	CcSEcCtD
Nilutamide—Visual disturbance—Varenicline—nicotine dependence	0.0239	0.0321	CcSEcCtD
Nilutamide—Arthritis—Varenicline—nicotine dependence	0.0233	0.0313	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.0226	0.0304	CcSEcCtD
Nilutamide—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.0225	0.0302	CcSEcCtD
Nilutamide—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0221	0.0862	CbGpPWpGaD
Nilutamide—Dry skin—Varenicline—nicotine dependence	0.0208	0.0279	CcSEcCtD
Nilutamide—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0201	0.0786	CbGpPWpGaD
Nilutamide—Angina pectoris—Varenicline—nicotine dependence	0.0191	0.0256	CcSEcCtD
Nilutamide—Erectile dysfunction—Varenicline—nicotine dependence	0.018	0.0242	CcSEcCtD
Nilutamide—Hyperglycaemia—Varenicline—nicotine dependence	0.0177	0.0237	CcSEcCtD
Nilutamide—Depression—Varenicline—nicotine dependence	0.0174	0.0234	CcSEcCtD
Nilutamide—Hypoaesthesia—Varenicline—nicotine dependence	0.0156	0.021	CcSEcCtD
Nilutamide—Urinary tract disorder—Varenicline—nicotine dependence	0.0155	0.0208	CcSEcCtD
Nilutamide—Oedema peripheral—Varenicline—nicotine dependence	0.0154	0.0207	CcSEcCtD
Nilutamide—Urethral disorder—Varenicline—nicotine dependence	0.0154	0.0206	CcSEcCtD
Nilutamide—CYP2C8—Xenobiotics—CYP2A7—nicotine dependence	0.0153	0.0599	CbGpPWpGaD
Nilutamide—Visual impairment—Varenicline—nicotine dependence	0.0151	0.0203	CcSEcCtD
Nilutamide—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.0137	0.0534	CbGpPWpGaD
Nilutamide—Back pain—Varenicline—nicotine dependence	0.0132	0.0177	CcSEcCtD
Nilutamide—Ill-defined disorder—Varenicline—nicotine dependence	0.0127	0.017	CcSEcCtD
Nilutamide—Anaemia—Varenicline—nicotine dependence	0.0126	0.0169	CcSEcCtD
Nilutamide—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.0125	0.0487	CbGpPWpGaD
Nilutamide—Malaise—Varenicline—nicotine dependence	0.0123	0.0165	CcSEcCtD
Nilutamide—Syncope—Varenicline—nicotine dependence	0.0122	0.0164	CcSEcCtD
Nilutamide—Loss of consciousness—Varenicline—nicotine dependence	0.012	0.0161	CcSEcCtD
Nilutamide—Cough—Varenicline—nicotine dependence	0.0119	0.016	CcSEcCtD
Nilutamide—Hypertension—Varenicline—nicotine dependence	0.0118	0.0158	CcSEcCtD
Nilutamide—Chest pain—Varenicline—nicotine dependence	0.0116	0.0156	CcSEcCtD
Nilutamide—Discomfort—Varenicline—nicotine dependence	0.0115	0.0154	CcSEcCtD
Nilutamide—Dry mouth—Varenicline—nicotine dependence	0.0114	0.0153	CcSEcCtD
Nilutamide—Oedema—Varenicline—nicotine dependence	0.0111	0.015	CcSEcCtD
Nilutamide—Shock—Varenicline—nicotine dependence	0.011	0.0147	CcSEcCtD
Nilutamide—Hyperhidrosis—Varenicline—nicotine dependence	0.0108	0.0145	CcSEcCtD
Nilutamide—Anorexia—Varenicline—nicotine dependence	0.0106	0.0143	CcSEcCtD
Nilutamide—Insomnia—Varenicline—nicotine dependence	0.0101	0.0135	CcSEcCtD
Nilutamide—Dyspnoea—Varenicline—nicotine dependence	0.00992	0.0133	CcSEcCtD
Nilutamide—Dyspepsia—Varenicline—nicotine dependence	0.0098	0.0132	CcSEcCtD
Nilutamide—Decreased appetite—Varenicline—nicotine dependence	0.00968	0.013	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00961	0.0129	CcSEcCtD
Nilutamide—Pain—Varenicline—nicotine dependence	0.00952	0.0128	CcSEcCtD
Nilutamide—Constipation—Varenicline—nicotine dependence	0.00952	0.0128	CcSEcCtD
Nilutamide—Feeling abnormal—Varenicline—nicotine dependence	0.00917	0.0123	CcSEcCtD
Nilutamide—Gastrointestinal pain—Varenicline—nicotine dependence	0.0091	0.0122	CcSEcCtD
Nilutamide—Body temperature increased—Varenicline—nicotine dependence	0.0088	0.0118	CcSEcCtD
Nilutamide—Abdominal pain—Varenicline—nicotine dependence	0.0088	0.0118	CcSEcCtD
Nilutamide—Asthenia—Varenicline—nicotine dependence	0.00799	0.0107	CcSEcCtD
Nilutamide—Pruritus—Varenicline—nicotine dependence	0.00788	0.0106	CcSEcCtD
Nilutamide—Diarrhoea—Varenicline—nicotine dependence	0.00762	0.0102	CcSEcCtD
Nilutamide—Dizziness—Varenicline—nicotine dependence	0.00736	0.0099	CcSEcCtD
Nilutamide—Vomiting—Varenicline—nicotine dependence	0.00708	0.00951	CcSEcCtD
Nilutamide—Rash—Varenicline—nicotine dependence	0.00702	0.00944	CcSEcCtD
Nilutamide—Dermatitis—Varenicline—nicotine dependence	0.00701	0.00943	CcSEcCtD
Nilutamide—Headache—Varenicline—nicotine dependence	0.00697	0.00937	CcSEcCtD
Nilutamide—Nausea—Varenicline—nicotine dependence	0.00661	0.00889	CcSEcCtD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00637	0.0249	CbGpPWpGaD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00629	0.0245	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00608	0.0237	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00569	0.0222	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00561	0.0219	CbGpPWpGaD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00518	0.0202	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00516	0.0202	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00512	0.02	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00461	0.018	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0042	0.0164	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00405	0.0158	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00368	0.0144	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00291	0.0114	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.00274	0.0107	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00271	0.0106	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0026	0.0101	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00245	0.00956	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00241	0.00943	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00237	0.00924	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00223	0.00871	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0022	0.00859	CbGpPWpGaD
Nilutamide—AR—Gene Expression—CCAR1—nicotine dependence	0.002	0.00781	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000469	0.00183	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000419	0.00163	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000382	0.00149	CbGpPWpGaD
